Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is developing a drug targeting non-muscle invasive bladder cancer that CEO Roger DuMoulin-White says has shown super data compared to two Big Pharma drugs already approved by the FDA.  DuMoulin-White sat down with Proactive's Stephen Gunnion to discuss the company's
Full Story >>
Vote
+24